What is pharmacogenomics? How your genes affect medications
Pharmacogenomics is the study of how your genes affect the way you respond to medications — most famously, how fast or slow you break certain drugs down. It's one of the most practical corners of genetics, because clinicians already use it in real prescribing. It's also one to treat carefully: consumer raw data is a starting point, never a prescription. Here's what pharmacogenomics is, how it works, the classic examples, and why any medication question belongs with a professional.
This is educational information, not medical advice. Never start, stop, or change a medication based on your DNA raw data. Pharmacogenomic decisions need clinical-grade testing and a doctor or pharmacist — self-interpreting a raw file and acting on it is exactly what this field is not for.
What is pharmacogenomics?
To define pharmacogenomics simply: it is the study of how your genes influence your response to medications. The word combines pharmacology (the science of drugs) with genomics (the study of your genes), and the core idea is that the same dose of the same drug can affect two people quite differently — partly because of inherited differences in how their bodies handle it.
If you've ever wondered what are pharmacogenomics doing in a conversation about DNA, this is the answer: much of the effect comes down to the enzymes that process medications. When you swallow a pill, your body has to break it down (and sometimes switch it on) before clearing it out. Genes build the enzymes that do that work. When an inherited variant makes one of those enzymes faster, slower, or nearly inactive, the amount of active drug circulating in your bloodstream shifts — and so can the medication's effect or its side effects.
That's the whole concept in one sentence: your genes help set the speed of your personal drug-processing assembly line. The rest is detail about which genes, which drugs, and — crucially — in which direction.
How does pharmacogenomics work?
How does pharmacogenomics work at the level of the body? Most of the action happens in the liver, home to the cytochrome P450 (CYP) enzyme family — a set of proteins that does much of the body's chemical housekeeping, including metabolizing the drugs we take. A handful of these genes come up again and again in pharmacogenomics:
- CYP2D6 — processes a long list of common medications, including some antidepressants, antipsychotics, and pain relievers such as codeine.
- CYP2C19 — activates the antiplatelet drug clopidogrel and clears certain PPIs and antidepressants. (We go deep on this one in CYP2C19 in your 23andMe raw data.)
- CYP2C9 — helps process the blood thinner warfarin and some anti-inflammatories.
You inherit one copy of each gene from each parent, and the combination of those two copies predicts roughly how much working enzyme you produce. The field describes the result as a spectrum of metabolizer phenotypes:
| Metabolizer type | Enzyme activity | What it can mean |
|---|---|---|
| Poor | Very low or none | A drug that this enzyme clears may build up; a prodrug it activates may stay under-activated |
| Intermediate | Reduced | A milder version of the poor-metabolizer picture |
| Normal | Typical | The activity most dosing guidance assumes |
| Rapid | Increased | A drug may be cleared faster than expected |
| Ultrarapid | Highest | A drug may be cleared so fast a standard dose does less — or a prodrug activated so much it overshoots |
A few things are worth holding in mind about that table. These are predicted phenotypes — labels the field assigns based on genotype — not live measurements of how your liver is behaving today. Real-world activity is also shaped by other medications, liver health, and interacting drugs. And, most importantly, the direction of the effect depends on the drug. There's no universal "fast is good, slow is bad" rule, which is precisely why self-interpreting a raw file is so risky.
Prodrugs versus active drugs: why direction matters
The single most important idea in pharmacogenomics is that a slow enzyme can be helpful for one drug and unhelpful for another. It comes down to whether the medication arrives already active or has to be switched on.
- A prodrug is swallowed inactive and must be converted by the body into its working form. Clopidogrel is the textbook case: CYP2C19 helps turn it into its active antiplatelet compound. For a prodrug, low enzyme activity can mean less active drug is produced.
- An active drug is already working when you take it, and the enzyme's job is to break it down and remove it. Here the logic flips: low activity can mean the drug is cleared slowly and builds up, while very high activity can clear it so fast that a standard dose does less.
That reversal is exactly why "reduced CYP2C19 activity" or "poor metabolizer" tells you nothing actionable on its own. You have to know which medication is in question and whether it's a prodrug or an active drug — and even then, the real decision involves clinical context a genotype can't supply. This is the kind of reasoning a doctor or pharmacist is trained to do, and the kind that goes wrong when people try to self-interpret.
Pharmacogenomics examples
Here are the best-established pharmacogenomics examples — the ones clinicians and guidelines actually use. They're included to explain why this field exists, not as a cue to check your own file and act on it.
| Gene | Example medication | What it affects |
|---|---|---|
| CYP2C19 | Clopidogrel (Plavix) | Activates this antiplatelet prodrug; low activity can mean a reduced antiplatelet effect |
| CYP2C9 + VKORC1 | Warfarin | Together they influence sensitivity to this blood thinner and the dose that suits a person |
| SLCO1B1 | Some statins (e.g. simvastatin) | Affects how much statin reaches the bloodstream, relevant to muscle-related side-effect risk |
| TPMT | Thiopurines (azathioprine, mercaptopurine) | Very low activity can raise the risk of serious toxicity, so activity is often checked before use |
| DPYD | 5-fluorouracil, capecitabine | Certain variants slow the breakdown of these chemotherapy drugs, raising toxicity risk |
| CYP2D6 | Codeine, some antidepressants | Changes how codeine is converted to morphine and how several other drugs are cleared |
A little more on the standouts:
- Clopidogrel + CYP2C19. Because clopidogrel is a prodrug, poor metabolizers may get less of the active compound. This is documented well enough that clinicians sometimes order CYP2C19 testing before relying on it in certain situations.
- Warfarin + VKORC1 / CYP2C9. Warfarin is famously dose-sensitive, and these two genes are among the factors that influence how much a person needs — one reason dosing is done carefully by a prescriber, with monitoring.
- Statins + SLCO1B1. This gene affects how much of certain statins reaches the blood, which is relevant to the risk of muscle-related side effects.
- Thiopurines + TPMT and 5-FU + DPYD. These are the sharpest examples of why pharmacogenomics is treated as clinical-grade: very low enzyme activity can turn a standard dose into a dangerous one, so activity is often assessed before treatment.
Notice the pattern: every example lives inside a clinical decision, keyed to validated testing and run by a professional. None of them is a self-service instruction sheet.
Worth repeating: even the clearest examples above — clopidogrel, TPMT, DPYD — are illustrations of why a clinician might test, using validated methods, before making a prescribing choice. They are never a reason to change anything on your own.
Is it the same as pharmacogenetics?
You'll see both pharmacogenomics and pharmacogenetics, and in everyday use they mean the same thing. The traditional distinction is one of scope: pharmacogenetics looks at how a single gene affects a drug response, while pharmacogenomics is the broader study of how many genes — up to the whole genome — shape how you respond to medications. As sequencing has grown cheaper and more genes have been linked to drug response, the two ideas have effectively merged. For a curious reader, treating them as synonyms is fine.
Can 23andMe raw data tell me my drug response?
Short answer: not reliably. Consumer DNA files from 23andMe and AncestryDNA are generated by genotyping arrays — chips that read a predetermined set of positions rather than sequencing your genome fully. For pharmacogenomics that creates three practical limits:
- Partial coverage. Arrays report only some of the relevant variants and star alleles. If an important loss-of-function allele isn't on the chip, your file simply won't mention it — which can make the picture look tidier than it is.
- Single-position calls can be wrong. Arrays occasionally miscall an individual marker. For casual traits that's a curiosity; for a gene that touches medication response, one miscalled position is a reason to distrust a raw-data readout on its own.
- No clinical validation. Consumer arrays aren't run, interpreted, or reported under the standards used for clinical pharmacogenetic testing. 23andMe's own materials are explicit that raw data isn't for medical use — and that's the correct framing.
So raw data is a hint, not a result. A clinical pharmacogenetic test is a different instrument entirely: it targets the relevant alleles deliberately, runs under quality controls, and produces a report a prescriber can rely on. If you want to explore what your file contains — as a prompt for a conversation, not a conclusion — you can read it privately in our free DNA explorer, which parses the file on your device with nothing uploaded, or browse well-studied markers in the Quanome gene library. Curious about a lighter, non-medication example of gene-drug-style biology? CYP1A2 and caffeine is a gentler place to start.
The role of CPIC and clinical testing
When a clinician does have a validated result in hand, they don't have to improvise what it means. The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes peer-reviewed, freely available guidelines that translate a known genotype into concrete prescribing guidance — for clopidogrel, warfarin, thiopurines, certain antidepressants, and more.
Two features of CPIC are worth understanding:
- CPIC guidance is written for clinicians and designed for use with clinical-grade test results, not consumer raw data. It assumes the genotype feeding it was established by validated testing.
- It is applied by a prescriber weighing the genotype alongside your diagnosis, other medications, and everything else in your chart. The guideline is one input into a professional decision — not a self-service instruction.
In other words, the infrastructure to use pharmacogenomics responsibly already exists — it just lives in the clinic, keyed to proper testing, and operated by professionals. That's the pathway your raw-data curiosity should feed into.
Should you change a medication based on this? (No.)
This deserves its own heading because it's the one thing that matters most. Never start, stop, adjust, or dose any medication based on consumer raw data — including deciding whether a drug will "work" for you. The examples in this article are real and repeatable, which is exactly what makes them tempting to act on. But the leap from "my file shows a variant" to "this drug is wrong for me" is a clinical judgment that depends on validated testing, the specific drug, the dose, and everything else going on in your health.
The healthiest way to hold a pharmacogenomics result is as a question, not an answer: "My raw data hinted I might be a poor metabolizer for CYP2C19 — is that worth confirming for the medication I'm on?" That single sentence, brought to a doctor or pharmacist, is exactly what consumer genetics is good for. They can decide whether validated testing is warranted, interpret it against CPIC guidance, and factor in the rest of your health. Acting on it is their job, not a raw-data lookup's.
For the rest of what your file holds, see our complete guide to analyzing 23andMe raw data, or bring your genetics, labs, and Apple Health together on one private, on-device timeline with Quanome.
Explore your markers privately, then talk to a professional
Quanome reads your raw DNA on your device and surfaces well-studied markers — with nothing uploaded. Pharmacogenomics is clinical-grade territory, so confirm anything about your medications with a doctor or pharmacist. Learn more about Quanome →
Frequently asked questions
What is pharmacogenomics in simple terms?
Pharmacogenomics is the study of how your genes affect the way your body responds to medications — especially how quickly you break a drug down. Because inherited differences in certain enzymes can change how much active drug ends up in your bloodstream, two people on the same dose can respond quite differently. It is one of the more established areas of genetics, and clinicians already use it in real prescribing decisions.
How does pharmacogenomics work?
Many medications are processed by enzymes in your liver, especially the cytochrome P450 family (genes like CYP2D6, CYP2C19, and CYP2C9). Inherited variants can make an enzyme faster, slower, or nearly inactive, which shifts how much active drug circulates and for how long. Whether that matters — and in which direction — depends entirely on the specific medication, so it is a question for a clinician, not a raw-data lookup.
What are some pharmacogenomics examples?
Well-studied examples include clopidogrel (Plavix) with CYP2C19, warfarin with VKORC1 and CYP2C9, some statins with SLCO1B1, thiopurine drugs like azathioprine with TPMT, and the chemotherapy agent 5-fluorouracil with DPYD. In each case an inherited difference can change how a person responds to that specific drug — which is exactly why validated testing and a prescriber are involved.
Is pharmacogenomics the same as pharmacogenetics?
The terms are often used interchangeably. Pharmacogenetics traditionally refers to how a single gene affects a drug response, while pharmacogenomics is the broader study of how many genes — or the whole genome — influence how you respond to medications. In everyday use, and in most consumer contexts, you can treat them as the same idea.
Can 23andMe raw data tell me my drug response?
Not reliably. Consumer arrays like 23andMe and AncestryDNA genotype a limited set of positions, may miss important star alleles, and can occasionally miscall a marker — and they are not run under clinical quality controls. Raw data can be an interesting prompt for a conversation, but it is a hint, not a clinical result, and it does not tell you how a medication will work for you.
Should I change my medication based on my DNA raw data?
No. Never start, stop, adjust, or dose any medication based on consumer raw data — including deciding whether a drug will 'work' for you. Pharmacogenomic decisions require clinical-grade testing interpreted by a doctor or pharmacist alongside the rest of your health. This is educational information only.
What is a metabolizer type?
For many drug-processing genes, the field describes a spectrum of metabolizer phenotypes — poor, intermediate, normal, rapid, and ultrarapid — based on the two gene copies you inherit. These are predicted labels from genotype, not measurements of how your body is behaving today, and real-world activity is also shaped by other medications, liver health, and interacting drugs.
What is CPIC?
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes peer-reviewed, freely available guidelines that translate a known genotype into prescribing guidance for clinicians. CPIC guidelines are designed for use with clinical-grade test results — not consumer raw data — and are applied by a prescriber, not the patient.
Quanome is live — free on iPhone and Android
Make sense of your DNA and health data privately. Download Quanome free on the App Store or Google Play.
Quanome is free on the App Store and Google Play. Want product news too? Leave your email below.